) The overall goal of the Program in Immunology and Immunotherapy is to understand the basic elements of immunity and the mechanisms by which cancer cells evade the immune system so that new intervention strategies can be developed to reduce the cancer burden. This is accomplished programmatically by fostering collaborations and encouraging a broad range of investigations into the connections between immunity and cancer. The University of Colorado Cancer Center leadership reorganized the structure of the Cancer Center in 1998 and 1999 in order to better promote translational research and collaborations, and to strengthen the cancer focus. The old Melanoma and Neuro-oncology focus groups from Adult Clinical Oncology were combined with the Immunology Program to form the new Immunology and Immunotherapy Program. As a consequence, the Program in Immunology and Immunotherapy now has 35 full members holding primary appointments in the Departments of Cell and Structural Biology, Dermatology, Immunology, Medicine, Neurology, Pathology, Pediatrics, Radiology, Radiation Oncology, and Surgery. The group includes the Chair of the Department of Immunology and three members of the National Academy of Sciences. Program members have nearly $12 million in annual direct costs from more than ninety grants. Since the last review, there has been an increase in grants from all agencies, especially the NCI, and NIH. Program members contributed 250 publications, approximately 40 percent involving collaborations with two or more Cancer Center members as authors. Program project initiatives in bone marrow transplantation, melanoma therapy, and control of cell death and differentiation were undertaken. Recruitment of new faculty with interests in human tumor immunology and immunotherapy has been initiated. The Cancer Center provided seed funding to support pilot projects that might evolve into a program project application. Clinical trials in breast, brain, and skin cancer immunotherapy are underway, and promising pre-clinical studies on lung cancer treatment have been made.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-15
Application #
6589982
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776

Showing the most recent 10 out of 1634 publications